PUBLISHED DATE : Jun 2022 | Pages : 191
Fill out your details & get your free sample
Cervical Cancer Therapeutics Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2022–2027
191 Pages
10 Tables
124 Charts
3 Regions
8 Countries
30 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 7.1 Billion |
| Market Size (2021) | USD 5.5 Billion |
| CAGR (2022-2027) | 4.27% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Drug Class (Chemotherapy, Targeted therapy), Histology Type (Squamous cell carcinoma, Adenocarcinoma, and Adeno, Distribution Channel (Hospital & Clinics, Retail & Specialty Pharmacies), and Age Group (Below 29 years, 30-49 years, and 50+ years) |
| Geographic Analysis | North America, Europe, APAC |
| Countries Covered | United States, France, Germany, Italy, UK, Spain, China, and Japan |
The cervical cancer therapeutics market size was valued at USD 5.5 billion in 2021 and is expected to reach USD 7.1 billion by 2027, growing at a CAGR of 4.14% during 2021-2027. Cervical cancer is a disease in which malignant cells are formed in the tissues of the cervix, the lower part of the uterus that connects to the vagina. Human papillomavirus (HPV) infection is the major risk factor for cervical cancer.
According to Arizton's estimates, the diagnosed incident cases of cervical cancer were high in China, followed by the U.S. and Japan in 2020. The increasing prevalence of HIV (Human Immunodeficiency Virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally; HIV weakens the immune system, which increases the likelihood of cervical cancer. Surgery is the standard of care for the treatment of early-stage, while chemoradiation is the most common treatment modality for locally advanced disease. In the U.S., the approvals of Keytruda as first-line therapy and Tivdak as second-line therapy in 2021 wholly altered the treatment paradigm for recurrent and distally metastatic disease. Before the approval of Keytruda in the first line, patients received chemotherapy with Avastin, which remains the treatment of choice outside the U.S.
Early Detection of Disease: More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The Pap smear test, the most effective tool for diagnosing HPV in the early stage, is the most revenue-generating segment.
Increasing Prevalence of Cervical cancer: The market study has been witnessing considerable growth, attributed to the increasing prevalence of cervical cancer among women worldwide. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide, and about 311 000 women died due to improper detection at the early stages of the disease.
Launch of Novel Biologic Therapeutics: The USFDA has approved biologics such as Keytruda (pembrolizumab) in 2018 & 2021 and Tivdak (tisotumab-vedotin-tftv) in 2021 for the treatment of cervical cancer. The launch of approved biological therapies and further uptake in cell-based therapies will lead to significant cervical cancer therapeutics market growth.
Drug Class: Chemotherapeutic drugs are expected to dominate the global cervical cancer therapeutics market. However, the targeted therapies are expected to be the fastest-growing segment during the forecast period. Recently approved biological drugs such as Keytruda (pembrolizumab) and Tivdak (tisotumab-vedotin-tftv) are expected to drive the targeted therapies segment during the forecast period.
Histology type: Among the histology type, Squamous cell Carcinoma is expected to account for a significant share of the global cervical cancer therapeutics market. However, Adenocarcinoma is the fastest-growing segment during the forecast period due to its aggressive nature.
Age Group: Among the Age group, women aged 50 years are expected to account for a significant portion of the global cervical cancer therapeutics market share. However, women between the age of 30 – 49 years are expected to be the fastest-growing segment during the forecast period.
Distribution type: Among the distribution type, Retail & Specialty pharmacy services are expected to dominate the cervical cancer therapeutics market. According to the National Comprehensive Cancer Network Specialty Pharmacy Task Force, more than 80% of managed care organizations reported contracting with specialty pharmacy providers for their oncology business, and 51.4% reported using a single, preferred specialty provider for all limited-distribution drugs.
Geography: The U.S. dominates the cervical cancer therapeutics market due to the rise in the healthcare affordability in the U.S., rise in the knowledge and rise in the awareness amongst the people, and rises in the technological advancement in this region. However, China is expected to grow faster with a high CAGR in the cervical cancer drug market due to a rise in healthcare access and quality, increased awareness about disease management, and rising healthcare expenditure. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.
Cervical Cancer Therapeutics: Pipeline Scenario The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for cervical cancer are in the Phase II stage. The distribution of the pipeline drugs across Phase I-IV is dominated by Phase II (35.5%), followed by Phase I (31.36%), and then Phase III (7.10%).
Cervical Cancer Therapeutics: Clinical Trials Scenario
The clinical trial portfolio contains 282+ trials in various phases of development. The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of problems for cervical cancer have been in the early and mid-phases of development, with 94% of issues in Phase I-II and only 6% in Phase III-IV. The U.S. has a substantial lead in the number of cervical cancer clinical trials globally. The U.K. leads the primary European markets, while China has the top spot in Asia. Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti–P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer. For instance, Atezolizumab and prolgolimab (BCD-100) combined with chemotherapy with or without bevacizumab and pembrolizumab with chemoradiotherapy are ongoing. In addition, several trials are examining novel combinations in this space.
The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer. The U.S. Food and Drug Administration (FDA) approved the antiangiogenic agent bevacizumab (Avastin) to treat persistent, recurrent, or metastatic cervical cancer in 2014. This marked the arrival of biologics in this treatment landscape. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. The FDA approved Keytruda (pembrolizumab) in 2018 and Tivdak (tisotumab-vedotin-tftv) in 2021 to treat cervical cancer. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
The cervical cancer portfolio contains a total of 169+ assets which are in various phases of development. More than 40% of the pipeline is for cervical cancer. Next-generation biotherapeutics (biologics) are increasingly deployed, including cell and gene therapies, antibodies, antibody-drug conjugates, and bispecific antibodies. The emerging therapeutics for cervical cancer include cadonilimab, socazolimab, prolgolimab, durvalumab, ocrelizumab, serplulimab, catequentinib, and others. The launch of these novel emerging drugs will shift the cervical cancer treatment paradigm shortly. With more than 169 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating cervical cancer.
The prominent players offering drugs in the cervical cancer treatment market include Regeneron Pharmaceuticals, Akesobio, AstraZeneca, Merck KGaA, Seagen Inc., Qilu Pharmaceutical Co., Ltd., Roche, Guangzhou Gloria Biosciences Co., Ltd., Lee's Pharmaceutical, BeiGene, Helix Biotech, Biocad, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Innovent Biologics and many others. These players are focused on R&D initiatives to develop technologically advanced and innovative cervical cancer drugs and are also entering into collaborations to maintain their position in the market.
Frequently Asked Questions
WHAT IS THE MARKET SIZE OF THE CERVICAL CANCER THERAPEUTICS MARKET?
The cervical cancer therapeutics market size was valued at USD 5538.71 million in 2021 and is expected to reach USD 7117.40 million by 2027.
WHAT IS THE GROWTH RATE OF THE CERVICAL CANCER THERAPEUTICS MARKET?
The cervical cancer therapeutics market to grow at a CAGR of 4.14% during 2021-2027.
WHO ARE THE KEY PLAYERS IN THE CERVICAL CANCER THERAPEUTICS MARKET?
Key players include Merck & Co Inc (Merck), Seagen Inc (Seagen), F. Hoffmann-La Roche Ltd (Roche), Pfizer Inc (Pfizer), and Amgen Inc.
WHAT ARE THE SEGMENTS COVERED IN THE CERVICAL CANCER THERAPEUTICS MARKET?
Segments include drug class, histology type, distribution channel, age group, and region.
The cervical cancer therapeutics market size was valued at USD 5.5 billion in 2021 and is expected to reach USD 7.1 billion by 2027, growing at a CAGR of 4.14% during 2021-2027.
The following factors are likely to contribute to the growth of the market during the forecast period:
The market for cervical cancer is increasing faster. The trend is likely to continue during the forecast period due to the rising rise in the incidence of HIV in women and the incidence of cervical cancer across the world.
Base Year: 2021
Forecast Year: 2022-2027
Key Vendors:
Other Prominent Vendors
Segmentation by Drug Class
Segmentation by Histology Type
Segmentation by Distribution Channel
Segmentation by Age Group
Segmentation by Region
CHAPTER – 1: CERVICAL CANCER OVERVIEW
CHAPTER – 2: CERVICAL CANCER EPIDEMIOLOGY & OVERVIEW
CHAPTER – 3: CERVICAL CANCER MARKET SIZE & OVERVIEW
CHAPTER – 4: CERVICAL CANCER MARKETED DRUGS OVERVIEW
CHAPTER – 5: CERVICAL CANCER PIPELINE DRUGS OVERVIEW
CHAPTER – 6: CERVICAL CANCER CLINICAL TRIALS OVERVIEW
CHAPTER – 7: CERVICAL CANCER MARKET DYNAMICS
CHAPTER – 8: CERVICAL CANCER COMPETITIVE LANDSCAPE
CHAPTER – 9: CERVICAL CANCER MISCELLANEOUS
CHAPTER – 10: APPENDIX
LIST OF EXHIBITS
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 6: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN 8 MAJOR MARKETS (2020 – 2021)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2018 – 2027)
Exhibit 8: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2018 – 2020)
Exhibit 9: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN US (2021 – 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2018 – 2027)
Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2018 – 2020)
Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN US (2020 – 2021)
Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2018 – 2027)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2018 – 2020)
Exhibit 15: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN CHINA (2021 – 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 17: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2018 – 2020)
Exhibit 18: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN CHINA (2020 – 2021)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2018 – 2027)
Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2018 – 2020)
Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN JAPAN (2021 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 23: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2018 – 2020)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN JAPAN (2020 – 2021)
Exhibit 25: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2018 – 2027)
Exhibit 26: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2018 – 2020)
Exhibit 27: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN GERMANY (2021 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2018 – 2020)
Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN GERMANY (2020 – 2021)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2018 – 2027)
Exhibit 32: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2018 – 2020)
Exhibit 33: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN UK (2021 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2018 – 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2018 – 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN UK (2020 – 2021)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2018 – 2027)
Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2018 – 2020)
Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN FRANCE (2021 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 41: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2018 – 2020)
Exhibit 42: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN FRANCE (2020 – 2021)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2018 – 2027)
Exhibit 44: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2018 – 2020)
Exhibit 45: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN ITALY (2021 – 2027)
Exhibit 46: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2018 – 2020)
Exhibit 48: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN ITALY (2020 – 2021)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2018 – 2027)
Exhibit 50: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2018 – 2020)
Exhibit 51: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CERVICAL CANCER IN SPAIN (2021 – 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 53: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2018 – 2020)
Exhibit 54: COMPARATIVE ANALYSIS OF INCIDENCE OF CERVICAL CANCER BY AGE GROUP IN SPAIN (2021 – 2027)
Exhibit 55: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 56: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN 8 MAJOR MARKETS ( 2018 – 2020)
Exhibit 57: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 58: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 59: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 60: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 61: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN US (2018 – 2027)
Exhibit 62: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 63: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN US (2021 – 2027)
Exhibit 64: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 65: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN US (2021 – 2027)
Exhibit 66: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN US (2021 – 2027)
Exhibit 67: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN CHINA (2018 – 2027)
Exhibit 68: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 69: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN CHINA (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 71: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN CHINA (2021 – 2027)
Exhibit 72: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN CHINA (2021 – 2027)
Exhibit 73: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN JAPAN (2018 – 2027)
Exhibit 74: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 75: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN JAPAN (2021 – 2027)
Exhibit 76: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 77: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN JAPAN (2021 – 2027)
Exhibit 78: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN JAPAN (2021 – 2027)
Exhibit 79: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN GERMANY (2018 – 2027)
Exhibit 80: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 81: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN GERMANY (2021 – 2027)
Exhibit 82: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 83: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN GERMANY (2021 – 2027)
Exhibit 84: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN GERMANY (2021 – 2027)
Exhibit 85: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN UK (2018 – 2027)
Exhibit 86: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 87: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN UK (2021 – 2027)
Exhibit 88: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 89: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN UK (2021 – 2027)
Exhibit 90: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN UK (2021 – 2027)
Exhibit 91: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN FRANCE (2018 – 2027)
Exhibit 92: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 93: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN FRANCE (2021 – 2027)
Exhibit 94: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 95: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN FRANCE (2021 – 2027)
Exhibit 96: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN FRANCE (2021 – 2027)
Exhibit 97: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN ITALY (2018 – 2027)
Exhibit 98: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 99: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN ITALY (2021 – 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN ITALY (2021 – 2027)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN ITALY (2021 – 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET IN SPAIN (2018 – 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY AGE GROUP IN SPAIN (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET HISTOLOGY IN SPAIN (2021 – 2027)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION TYPE IN SPAIN (2021 – 2027)
Exhibit 109: MARKETED DRUGS OVERVIEW IN CERVICAL CANCER TREATMENT MARKET
Exhibit 110: MARKETED DRUGS OVERVIEW SNAPSHOT IN CERVICAL CANCER TREATMENT
Exhibit 111: PIPELINE DRUGS OVERVIEW IN CERVICAL CANCER TREATMENT MARKET
Exhibit 112: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 113: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 114: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 115: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 116: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 117: CERVICAL CANCER PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 118: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 119: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 120: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 121: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 122: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 123: CERVICAL CANCER CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 124: COMPETITIVE ASSESSMENT OF CERVICAL CANCER TREATMENT MARKET
TABLES
Table 1: KEY MARKET DRIVERS IN CERVICAL CANCER TREATMENT MARKET
Table 2: KEY MARKET CONSTRAINTS IN CERVICAL CANCER TREATMENT MARKET
Table 3: KEY MARKET TRENDS IN CERVICAL CANCER TREATMENT MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN CERVICAL CANCER
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN CERVICAL CANCER
Table 6: KEY MILESTONES IN CERVICAL CANCER TREATMENT MARKET
Table 7: KEY DEALS & COLLABORATIONS IN CERVICAL CANCER TREATMENT MARKET
Table 8: KEY POTENTIAL TRIAL COMPARISONS IN CERVICAL CANCER
Table 9: KEY INACTIVE/DISCONTINUED PRODUCTS IN CERVICAL CANCER TREATMENT
Table 10: KEY UNMET NEEDS & STRATEGIC RECOMMENDATIONS IN CERVICAL CANCER TREATMENT
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
